title: [Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes].
abstract: Goal of this study was to monitor levels of serum neopterin and soluble interleukin-2 receptor (sIL-2r) and to evaluate their importance in monitoring activity of systemic lupus erythematodes (SLE). Levels of serum neopterin, anti-dsDNA antibodies, C3, C4 complement components, nucleosomes antibodies, IL-10, fas ligand, soluble thrombomodulin, sVCAM-1, and sICAM-1 were measured in a group of 52 patients with SLE. Positive correlations were proved between neopterin concentrations and disease activity (ECLAM), levels of sVCAM-1, sICAM-1, sIL-2r and thrombomodulin, further between sIL-2r level and disease activity (ECLAM), and concentrations sVCAM-1, sICAM-1 and neopterin. Higher values of neopterin and sIL-2r levels were identified in patients with lupus nephritis compared to patients without kidney impairment. Statistically significant differences were identified in levels of neopterin between a subgroup (A) with minimum disease activity and a subgroup (B) with increasing disease activity (p = 0.01) and a subgroup (C) with decreasing disease activity (p = 0.003 ) and a subgroup (LN) with lupus nephritis (0.007) during the first and the third series of measurements. sIL2r levels which had in all subgroups very varied values were the lowest in the subgroup A with minimum disease activity during the whole time of monitoring. The highest levels reached the free receptor IL-2 in the subgroup B with increasing disease activity and in the subgroup with lupus nephritis. Statistically significant differences in values were identified between the subgroup A (non-active) and the subgroup LN (lupus nephritis) with p = 0.01 during the first set of the measurements. Fluctuation of sIL-2r levels in individual subgroups during the time of monitoring did not reach statistically important levels. In conclusion it could be said that potential practical utilization of the measurement of concentrations of the two mentioned molecules should be seen especially in monitoring disease activity because they don't contribute to SLE with needed information. Their always low values have favourable prognostic impact in monitoring patients with SLE and vise versa.
authors.affiliation: III. interní klinika Lékarské fakulty UP a FN, Olomouc.
authors.forename: P
authors.initials: P
authors.lastname: Horák
authors.forename: Z
authors.initials: Z
authors.lastname: Hermanová
authors.forename: M
authors.initials: M
authors.lastname: Ordeltová
authors.forename: L
authors.initials: L
authors.lastname: Faltýnek
authors.forename: L
authors.initials: L
authors.lastname: Kusá
authors.forename: M
authors.initials: M
authors.lastname: Budíková
authors.forename: V
authors.initials: V
authors.lastname: Vavrdová
authors.forename: D
authors.initials: D
authors.lastname: Opíchalová
authors.forename: H
authors.initials: H
authors.lastname: Ciferská
authors.forename: V
authors.initials: V
authors.lastname: Scudla
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis*; D008181:Lupus Nephritis / Q000097:blood / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D019798:Neopterin / Q000097:blood*; D011379:Prognosis
chemical_list: D015415:Biomarkers; D007376:Interleukin-2; D019798:Neopterin